Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19058528 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19037555 | MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN HUMANS AND IMPROVED CELL CULTIVATION METHODS | January 2025 | January 2026 | Allow | 11 | 1 | 0 | Yes | No |
| 19032762 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | January 2025 | January 2026 | Allow | 12 | 2 | 1 | Yes | No |
| 18982853 | PHOSPHORYLATED ANTIGEN AND ANTIBODY AT SER23 SITE OF PGAM1 PROTEIN AS WELL AS PREPARATION METHODS AND APPLICATIONS | December 2024 | August 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18861616 | COLLAGEN HYDROLYSATE COMPOSITION FOR REDUCING JOINT PAIN AFTER EXERCISE | October 2024 | June 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18861520 | HYDROGEL COMPOSITION, METHOD FOR PRODUCING THE SAME, AND USE THEREOF FOR STEM CELL MIMETIC PEPTIDE SUPPLEMENTATION | October 2024 | January 2026 | Abandon | 32 | 1 | 1 | No | No |
| 18783156 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | July 2024 | June 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18750971 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18746802 | Immunoconjugates | June 2024 | October 2025 | Allow | 16 | 0 | 1 | Yes | No |
| 18627131 | SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | April 2024 | July 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18425954 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | January 2024 | August 2025 | Allow | 19 | 0 | 1 | Yes | No |
| 18407929 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOF | January 2024 | December 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18406593 | TREATMENT FOR BONE DISEASES | January 2024 | March 2026 | Allow | 26 | 1 | 1 | Yes | No |
| 18391146 | METHODS AND COMPOSITIONS FOR REGENERATING TISSUES | December 2023 | December 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18492150 | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | October 2023 | July 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18488796 | COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORS | October 2023 | December 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18482891 | Compositions and Methods of Treatment for Various Conditions using High-Molecular Weight Hyaluronic Acid | October 2023 | May 2025 | Allow | 20 | 1 | 2 | Yes | No |
| 18279476 | LA PROTEIN AS A NOVEL REGULATOR OF OSTEOCLASTOGENESIS | August 2023 | November 2024 | Abandon | 15 | 1 | 1 | No | No |
| 18457861 | ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | August 2023 | March 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18352366 | TUNABLE SILK-BASED BIOMATERIALS WITH SACCHARIDE SUBSTITUTIONS, AND METHODS OF PRODUCING THE SAME | July 2023 | February 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18317277 | COMPOSITIONS FOR TREATING AUTOIMMUNE ARTHRITIS | May 2023 | August 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18034867 | BCMA/TACI ANTIGEN-BINDING MOLECULES | May 2023 | February 2026 | Allow | 33 | 0 | 0 | Yes | No |
| 18301839 | MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN HUMANS AND IMPROVED CELL CULTIVATION METHODS | April 2023 | October 2024 | Allow | 18 | 3 | 1 | Yes | No |
| 18031536 | HEMATOPOIETIC STEM CELL ENGRAFTMENT WITH A COMBINATION OF AGENTS | April 2023 | December 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 18177642 | CARTILAGE-HOMING PEPTIDES | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18175849 | Methods of Using IL-1beta Compounds | February 2023 | February 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18175163 | TWISTED GASTRULATION POLYPEPTIDES AND USES THEREOF | February 2023 | July 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18114832 | IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS | February 2023 | September 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 18166211 | ANTI-SCLEROSTIN ANTIBODIES AND METHODS OF USE | February 2023 | September 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 18165203 | METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST | February 2023 | February 2026 | Abandon | 36 | 3 | 1 | No | No |
| 18162769 | ANTI-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY | February 2023 | February 2026 | Allow | 36 | 0 | 1 | Yes | No |
| 18157689 | SAPOSIN C PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER | January 2023 | September 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18088272 | DOSAGE REGIMEN FOR PEGYLATED INTERFERON | December 2022 | May 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18062608 | GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT | December 2022 | October 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17996920 | MECHANICAL AND BIOCHEMICAL ACTIVATION AND CONTROL OF SKELETAL STEM CELLS FOR CARTILAGE REGENERATION | October 2022 | March 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 18046810 | COMPOSITIONS AND METHODS FOR TARGETED THERAPEUTIC DELIVERY TO BONE | October 2022 | January 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 17903910 | COMPOSITIONS AND METHODS FOR DEGENERATIVE DISC REGENERATION | September 2022 | March 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17776835 | COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES COMPRISING CCR2 | May 2022 | September 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17663384 | INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE | May 2022 | September 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17727876 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23 | April 2022 | September 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17724632 | Targeting Synaptogyrin-3 in Tauopathy Treatment | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17763902 | PHARMACEUTICAL COMPOSITION, COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN, FOR PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS AND BONE DISEASE | March 2022 | August 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17701748 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS | March 2022 | January 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17698602 | BONE REPAIR PRODUCT AND METHODS OF USE THEREOF | March 2022 | February 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17761485 | METHODS OF TREATING AUTOIMMUNE DISEASES USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | March 2022 | August 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17692818 | METHODS OF IMPROVING SPINAL FUSION WITH ABALOPARATIDE | March 2022 | August 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17633894 | HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS | February 2022 | February 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17618808 | RECOMBINANT FACTOR VIII-FC FOR TREATING HEMOPHILIA AND LOW BONE MINERAL DENSITY | December 2021 | October 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17616391 | ANTIBODY TARGETING THE VP-1 PROTEIN, FRAGMENTS THEREOF, AND USES OF SAME FOR DETECTING INFECTION WITH THE BK POLYOMAVIRUS | December 2021 | April 2025 | Allow | 40 | 0 | 0 | Yes | No |
| 17541992 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | December 2021 | September 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17616126 | USES OF SYNTHETIC LETHAL PARTNERS FOR TREATMENT OF CANCER | December 2021 | October 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17532584 | METHODS OF TREATING LIVER DISEASE | November 2021 | February 2026 | Allow | 51 | 1 | 1 | Yes | No |
| 17610319 | PEPTIDES AND CONJUGATES FOR TREATMENT OF ARTHRITIS | November 2021 | September 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17608351 | A STABLE LYOPHILIZED FORMULATION FOR HYBRID FC FUSED G-CSF | November 2021 | August 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17517533 | Method of Treating Osteoarthritis | November 2021 | December 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17598049 | COMPOSITION FOR PROMOTING CARTILAGE TISSUE REGENERATION | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17438634 | A METHOD FOR IMMUNOSUPPRESSION | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17470455 | BIOMARKERS AND METHODS FOR ASSESSING PSORIATIC ARTHRITIS DISEASE ACTIVITY | September 2021 | January 2024 | Abandon | 29 | 4 | 1 | No | No |
| 17465092 | METHOD FOR PURIFYING ACTIVE POLYPEPTIDES OR IMMUNOCONJUGATES | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17276916 | Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal Antibody | August 2021 | February 2025 | Allow | 47 | 0 | 1 | Yes | No |
| 17433295 | COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIES | August 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17432185 | ANTI-CSP ANTIBODY VARIANTS | August 2021 | June 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17402325 | MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELL RELATED CANCER CELLS AND USES THEREOF | August 2021 | April 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17430319 | HIGH AFFINITY ENGINEERED T-CELL RECEPTORS TARGETING CMV INFECTED CELLS | August 2021 | February 2026 | Allow | 54 | 2 | 1 | Yes | No |
| 17286355 | MARKER FOR DETERMING CRITICAL STAGE KIDNEY DISEASE | August 2021 | February 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17427559 | IMMUNOASSAY METHOD FOR FREE AIM IN BIOLOGICAL SAMPLE, AND ASSAY KIT | July 2021 | December 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17425599 | Composition for predicting clinical stage of Alzheimer's disease and kit using the same | July 2021 | December 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17443012 | COMPOSITION AND METHOD FOR DELIVERY OF BMP-2 AMPLIFIER/CO-ACTIVATOR FOR ENHANCEMENT OF OSTEOGENESIS | July 2021 | August 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17422556 | MUTATED INTERLEUKIN-34 (IL-34) POLYPEPTIDES AND USES THEREOF IN THERAPY | July 2021 | July 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17422075 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA | July 2021 | May 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17422033 | COMPOSITIONS AND METHODS FOR PREDICTING LUNG FUNCTION DECLINE IN IDIOPATHIC PULMONARY FIBROSIS | July 2021 | August 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17419932 | TEST METHOD FOR ULCERATIVE COLITIS AND PRIMARY SCLEROSING CHOLANGITIS | June 2021 | November 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17298865 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | June 2021 | November 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 17290016 | BIOMARKER PROTEINS FOR DIAGNOSING ALZHEIMER'S DEMENTIA AND USE THEREOF | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17288234 | MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CD20 | April 2021 | August 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17287367 | ANTI-IL-25 ANTIBODIES AND USE THEREOF | April 2021 | December 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17232145 | CYCLIC PEPTIDE FROM NOVEL BONE MORPHOGENETIC PROTEIN 2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | April 2021 | August 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17282577 | MENISCUS REGENERATION MATERIAL | April 2021 | June 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17211261 | SYSTEMS, COMPOSITIONS, AND METHODS FOR TRANSPLANTATION | March 2021 | November 2024 | Abandon | 44 | 3 | 1 | Yes | No |
| 17279359 | AXL-SPECIFIC ANTIBODIES FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17256509 | ANABOLIC TARGETING STEM CELL GENE THERAPY FOR OSTEOPOROSIS | December 2020 | November 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17053602 | USE OF CANAKINUMAB | November 2020 | February 2026 | Abandon | 60 | 3 | 1 | No | No |
| 17030416 | Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention | September 2020 | November 2024 | Abandon | 50 | 2 | 1 | Yes | No |
| 16967922 | METHODS FOR TREATING HETEROTOPIC OSSIFICATION | August 2020 | March 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 16945494 | METHODS OF REDUCING AGGREGATION OF IL-1RA | July 2020 | June 2025 | Abandon | 59 | 5 | 1 | Yes | No |
| 16960704 | CALRETICULIN BINDING CONSTRUCTS AND ENGINEERED T CELLS FOR THE TREATMENT OF DISEASES | July 2020 | December 2024 | Allow | 53 | 2 | 1 | Yes | No |
| 16863630 | INJECTABLE BONE MORPHOGENETIC PROTEIN | April 2020 | August 2024 | Allow | 52 | 4 | 1 | Yes | No |
| 16760731 | HETEROTOPIC OSSIFICATION AND METHOD OF TREATMENT | April 2020 | October 2024 | Allow | 54 | 4 | 1 | Yes | No |
| 16858301 | METHOD OF DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS | April 2020 | June 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16805481 | IL-4/IL-13 PATHWAY INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER | February 2020 | August 2024 | Allow | 54 | 3 | 1 | Yes | No |
| 16670395 | ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOF | October 2019 | October 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16659604 | NON-RESORBABLE BONE ALLOGRAFTS AND METHOD FOR MAKING SAME | October 2019 | October 2023 | Abandon | 48 | 2 | 0 | Yes | No |
| 16485574 | MYOMERGER POLYPEPTIDES, NUCLEIC ACID MOLECULES, CELLS, AND RELATED METHODS | August 2019 | August 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 15855398 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES, CONDITIONS OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | December 2017 | September 2019 | Allow | 21 | 0 | 1 | Yes | No |
| 15553930 | ANTI-TGF-BETA ANTIBODY FOR THE TREATMENT OF FANCONI ANEMIA | August 2017 | August 2019 | Allow | 24 | 1 | 1 | Yes | No |
| 15165150 | ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR | May 2016 | April 2018 | Allow | 22 | 0 | 1 | Yes | No |
| 14757770 | Method of treating skeletal dysplasias using vessel dilator | December 2015 | February 2018 | Allow | 26 | 2 | 1 | Yes | No |
| 14875812 | BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF | October 2015 | June 2017 | Allow | 21 | 0 | 1 | Yes | No |
| 14767117 | HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF | August 2015 | October 2018 | Allow | 38 | 1 | 1 | Yes | No |
| 14812908 | Immunoconjugates for the Treatment of Tumours | July 2015 | June 2017 | Allow | 22 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner XIE, XIAOZHEN.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner XIE, XIAOZHEN works in Art Unit 1674 and has examined 174 patent applications in our dataset. With an allowance rate of 86.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner XIE, XIAOZHEN's allowance rate of 86.8% places them in the 65% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by XIE, XIAOZHEN receive 2.40 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by XIE, XIAOZHEN is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +25.9% benefit to allowance rate for applications examined by XIE, XIAOZHEN. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.0% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.4% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 87.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 43.4% are granted (fully or in part). This grant rate is in the 36% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 20.7% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.